|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Large accelerated filer
o
|
Accelerated filer
x
|
|
Non-accelerated filer
o
|
Smaller reporting company
o
|
PART I – FINANCIAL INFORMATION
|
|
Item 1 – Condensed Consolidated Financial Statements (unaudited)
|
3
|
Condensed Consolidated Balance Sheets at June 30, 2010 and December 31, 2009
|
3
|
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and six months ended June 30, 2010 and 2009
|
4
|
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2010 and 2009
|
5
|
Notes to Condensed Consolidated Financial Statements
|
7
|
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
15
|
Item 3 – Quantitative and Qualitative Disclosures about Market Risks
|
23
|
Item 4 – Controls and Procedures
|
23
|
PART II – OTHER INFORMATION
|
|
Item 1 – Legal Proceedings
|
24
|
Item 1A – Risk Factors
|
24
|
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds
|
24
|
Item 3 – Defaults Upon Senior Securities
|
24
|
Item 4 – Removed and Reserved
|
24
|
Item 5 – Other Information
|
24
|
Item 6 – Exhibits
|
24
|
Signatures
|
27
|
June 30,
2010
|
December 31, 2009
|
||||||
ASSETS
|
|||||||
Current Assets:
|
|||||||
Cash and cash equivalents
|
$ | 30,483 | $ | 25,974 | |||
Accounts receivable, net of allowance for doubtful accounts and billing adjustments of $1,965 and $1,949, respectively
|
52,237 | 50,173 | |||||
Prepaid expenses
|
2,643 | 3,445 | |||||
Prepaid income taxes
|
1,671 | 4,717 | |||||
Deferred income tax assets
|
7,370 | 7,507 | |||||
Other
|
2,406 | 2,376 | |||||
Total current assets
|
96,810 | 94,192 | |||||
Property and Equipment, net
|
15,371 | 15,618 | |||||
Goodwill
|
209,209 | 202,814 | |||||
Identifiable intangible assets, net
|
25,196 | 25,523 | |||||
Other assets
|
4,608 | 5,315 | |||||
Total Assets
|
$ | 351,194 | $ | 343,462 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|||||||
Current Liabilities:
|
|||||||
Accounts payable
|
$ | 4,785 | $ | 4,164 | |||
Accrued payroll and contract professional pay
|
15,309 | 11,625 | |||||
Deferred compensation
|
1,963 | 2,070 | |||||
Workers’ compensation and medical malpractice loss reserves
|
10,500 | 10,349 | |||||
Other
|
3,270 | 3,746 | |||||
Total current liabilities
|
35,827 | 31,954 | |||||
Deferred income taxes
|
5,951 | 5,697 | |||||
Long-term debt
|
77,913 | 77,913 | |||||
Other long-term liabilities
|
3,601 | 1,237 | |||||
Total liabilities
|
123,292 | 116,801 | |||||
Commitments and Contingencies (Note 10)
|
|||||||
Stockholders’ Equity:
|
|||||||
Preferred Stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding
|
— | — | |||||
Common Stock, $0.01 par value, 75,000,000 shares authorized, 36,451,849 and 36,262,810 issued respectively
|
364 | 363 | |||||
Paid-in capital
|
222,429 | 220,082 | |||||
Retained earnings
|
5,728 | 5,090 | |||||
Accumulated other comprehensive income (loss)
|
(619 | ) | 1,126 | ||||
Total stockholders’ equity
|
227,902 | 226,661 | |||||
Total Liabilities and Stockholders’ Equity
|
$ | 351,194 | $ | 343,462 |
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
|||||||||||||||
2010
|
2009
|
2010
|
2009
|
|||||||||||||
Revenues
|
$ | 104,459 | $ | 101,834 | $ | 200,772 | $ | 218,636 | ||||||||
Cost of services
|
69,163 | 68,437 | 134,653 | 148,255 | ||||||||||||
Gross profit
|
35,296 | 33,397 | 66,119 | 70,381 | ||||||||||||
Selling, general and administrative expenses
|
31,964 | 29,985 | 61,795 | 63,114 | ||||||||||||
Operating income
|
3,332 | 3,412 | 4,324 | 7,267 | ||||||||||||
Interest expense
|
(1,607 | ) | (2,059 | ) | (3,167 | ) | (3,146 | ) | ||||||||
Interest income
|
32 | 47 | 64 | 103 | ||||||||||||
Income before income taxes
|
1,757 | 1,400 | 1,221 | 4,224 | ||||||||||||
Provision for income taxes
|
817 | 830 | 583 | 2,006 | ||||||||||||
Net income
|
$ | 940 | $ | 570 | $ | 638 | $ | 2,218 | ||||||||
Earnings per share:
|
||||||||||||||||
Basic
|
$ | 0.03 | $ | 0.02 | $ | 0.02 | $ | 0.06 | ||||||||
Diluted
|
$ | 0.03 | $ | 0.02 | $ | 0.02 | $ | 0.06 | ||||||||
Number of shares used to calculate earnings per share:
|
||||||||||||||||
Basic
|
36,427 | 36,181 | 36,394 | 36,011 | ||||||||||||
Diluted
|
37,150 | 36,385 | 37,165 | 36,188 |
Reconciliation of net income to comprehensive income (loss):
|
||||||||||||||||
Net income
|
$ | 940 | $ | 570 | $ | 638 | $ | 2,218 | ||||||||
Foreign currency translation gain (loss)
|
(995 | ) | 715 | (1,745 | ) | 199 | ||||||||||
Comprehensive income (loss)
|
$ | (55 | ) | $ | 1,285 | $ | (1,107 | ) | $ | 2,417 |
Six months ended June 30,
|
||||||||
2010
|
2009
|
|||||||
Cash Flows from Operating Activities:
|
||||||||
Net income
|
$ | 638 | $ | 2,218 | ||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Depreciation
|
2,902 | 2,972 | ||||||
Amortization of intangible assets
|
1,073 | 3,076 | ||||||
Provision for doubtful accounts and billing adjustments
|
175 | 126 | ||||||
Deferred income tax provision
|
— | (54 | ) | |||||
Stock-based compensation
|
3,219 | 2,207 | ||||||
Amortization of deferred loan costs
|
510 | 385 | ||||||
Change in fair value of interest rate swap
|
— | (1,345 | ) | |||||
Loss (gain) on officers’ life insurance policies
|
98 | (176 | ) | |||||
Gross excess tax benefits from stock-based compensation
|
(72 | ) | — | |||||
(Gain) loss on disposal of property and equipment
|
(30 | ) | 31 | |||||
Workers’ compensation and medical malpractice provision
|
1,989 | 2,661 | ||||||
Changes in operating assets and liabilities, net of effect of acquisitions:
|
||||||||
Accounts receivable
|
(1,424 | ) | 27,055 | |||||
Prepaid expenses
|
821 | 1,516 | ||||||
Prepaid income taxes
|
3,046 | 1,368 | ||||||
Accounts payable
|
620 | (317 | ) | |||||
Accrued payroll and contract professional pay
|
3,235 | (6,367 | ) | |||||
Deferred compensation
|
(107 | ) | 177 | |||||
Workers’ compensation and medical malpractice loss reserves
|
(1,840 | ) | (1,843 | ) | ||||
Other
|
(380 | ) | (2,288 | ) | ||||
Net cash provided by operating activities
|
14,473 | 31,402 | ||||||
Cash Flows from Investing Activities:
|
||||||||
Purchase of property and equipment
|
(2,836 | ) | (2,585 | ) | ||||
Net cash paid for acquisitions
|
(5,361 | ) | (5,300 | ) | ||||
Other
|
149 | 267 | ||||||
Net cash used in investing activities
|
(8,048 | ) | (7,618 | ) | ||||
Cash Flows from Financing Activities:
|
||||||||
Principal payments of long-term debt
|
— | (25,000 | ) | |||||
Proceeds from stock transactions
|
156 | 466 | ||||||
Payment of employment taxes related to release of restricted stock awards
|
(684 | ) | (207 | ) | ||||
Gross excess tax benefits from stock-based compensation
|
72 | — | ||||||
Payments for previous acquisitions
|
(22 | ) | — | |||||
Debt issuance or amendment costs
|
— | (1,065 | ) | |||||
Payments of other long-term liabilities
|
(34 | ) | (81 | ) | ||||
Net cash used in financing activities
|
(512 | ) | (25,887 | ) | ||||
Effect of exchange rate changes on cash and cash equivalents
|
(1,404 | ) | 337 | |||||
Net Increase (Decrease) in Cash and Cash Equivalents
|
4,509 | (1,766 | ) | |||||
Cash and Cash Equivalents at Beginning of Period
|
25,974 | 46,271 | ||||||
Cash and Cash Equivalents at End of Period
|
$ | 30,483 | $ | 44,505 |
Six months ended June 30,
|
||||||||
2010
|
2009
|
|||||||
Supplemental Disclosure of Cash Flow Information:
|
||||||||
Cash (received) paid for income taxes, net
|
$ | (2,450 | ) | $ | 726 | |||
Cash paid for interest, net
|
$ | 2,872 | $ | 2,616 | ||||
Supplemental Disclosure of Non-Cash Transactions:
|
||||||||
Accrued earn-out
|
$ | 2,300 | $ | — | ||||
Acquisition of property and equipment through accounts payable
|
$ | 408 | $ | 636 |
(Unaudited)
|
|||
Current assets
|
$ | 1,472 | |
Goodwill
|
6,395 | ||
Identifiable intangible assets
|
746 | ||
Long-term deposits and other long-term assets
|
32 | ||
Total assets acquired
|
$ | 8,645 | |
Current liabilities
|
$ | 731 | |
Long-term liabilities
|
253 | ||
Total liabilities assumed
|
984 | ||
Total purchase price
|
$ | 7,661 |
Life Sciences
|
Healthcare
|
Physician
|
IT and Engineering
|
Total
|
|||||||||||||||
Balance as of December 31, 2009
|
$ | 1,197 | $ | 15,912 | $ | 37,163 | $ | 148,542 | $ | 202,814 | |||||||||
Cambridge acquisition (see Note 3)
|
5,454 | ― | ― | 941 | 6,395 | ||||||||||||||
Balance as of June 30, 2010
|
$ | 6,651 | $ | 15,912 | $ | 37,163 | $ | 149,483 | $ | 209,209 |
June 30, 2010
|
December 31, 2009
|
|||||||||||||||||||||||
Estimated Useful Life
|
Gross Carrying Amount
|
Accumulated Amortization
|
Net Carrying Amount
|
Gross Carrying Amount
|
Accumulated Amortization
|
Net Carrying Amount
|
||||||||||||||||||
Intangible assets subject to amortization:
|
||||||||||||||||||||||||
Customer relations
|
3 months - 7 years
|
$ | 7,210 | $ | 6,571 | $ | 639 | $ | 6,660 | $ | 6,257 | $ | 403 | |||||||||||
Contractor relations
|
3 - 7 years
|
26,106 | 23,843 | 2,263 | 26,010 | 23,100 | 2,910 | |||||||||||||||||
NNon-compete agreements
|
2 - 3 years
|
440 | 346 | 94 | 340 | 330 | 10 | |||||||||||||||||
In-use software
|
2 years
|
500 | 500 | — | 500 | 500 | ― | |||||||||||||||||
34,256 | 31,260 | 2,996 | 33,510 | 30,187 | 3,323 | |||||||||||||||||||
Intangible assets not subject to amortization:
|
||||||||||||||||||||||||
Trademarks
|
22,200 | — | 22,200 | 22,200 | — | 22,200 | ||||||||||||||||||
Goodwill
|
209,209 | — | 209,209 | 202,814 | — | 202,814 | ||||||||||||||||||
Total
|
$ | 265,665 | $ | 31,260 | $ | 234,405 | $ | 258,524 | $ | 30,187 | $ | 228,337 |
June 30,
2010
|
December 31, 2009
|
||||||
Senior Secured Debt:
|
|||||||
$20 million revolving credit facility, due January 2012
|
$ | — | $ | — | |||
$145 million term loan facility, bearing interest at LIBOR (defined with a 3.0 percent floor) plus 3.75 percent, due January 2013
|
77,913 | 77,913 | |||||
Total
|
$ | 77,913 | $ | 77,913 | |||
Location of Gain (Loss) Recognized in Income on Derivative
|
Amount of Gain (Loss) Recognized in Income on Derivative
|
Amount of Gain(Loss)
Recognized in Income on Derivative
|
Amount of Gain(Loss)
Recognized in Income on Derivative
|
|||||||||||||
Three months ended
June 30,
|
Six months ended
June 30,
|
|||||||||||||||
2010
|
2009
|
2010
|
2009
|
|||||||||||||
Interest rate cap
|
Interest expense
|
$ | — | $ | — | $ | — | $ | — | |||||||
Interest rate swap
|
Interest expense
|
$ | — | $ | 685 | $ | — | $ | 1,345 |
June 30, 2010
|
December 31, 2009
|
|||||||||||||||
Carrying Amount
|
Fair Value
|
Carrying Amount
|
Fair Value
|
|||||||||||||
Life Insurance Policies
|
$ | 2,016 | $ | 2,016 | $ | 2,114 | $ | 2,114 | ||||||||
Long-Term Debt
|
$ | (77,913 | ) | $ | (76,354 | ) | $ | (77,913 | ) | $ | (75,576 | ) |
Three months ended
June 30,
|
Six months ended
June 30,
|
||||||||||||||
2010
|
2009
|
2010
|
2009
|
||||||||||||
Weighted average number of common shares outstanding used to compute basic earnings per share
|
36,427 | 36,181 | 36,394 | 36,011 | |||||||||||
Dilutive effect of stock-based awards
|
723 | 204 | 771 | 177 | |||||||||||
Number of shares used to compute diluted earnings per share
|
37,150 | 36,385 | 37,165 | 36,188 | |||||||||||
Three months ended
June 30,
|
Six months ended
June 30,
|
||||||||||||||
2010
|
2009
|
2010
|
2009
|
||||||||||||
Anti-dilutive common share equivalents outstanding
|
1,685 | 2,982 | 1,364 | 3,157 | |||||||||||
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
|||||||||||||||
2010
|
2009
|
2010
|
2009
|
|||||||||||||
Revenues:
|
||||||||||||||||
Life Sciences
|
$ | 25,511 | $ | 22,749 | $ | 48,561 | $ | 48,125 | ||||||||
Healthcare
|
19,300 | 23,252 | 37,876 | 54,763 | ||||||||||||
Physician
|
18,417 | 23,320 | 37,288 | 45,064 | ||||||||||||
IT and Engineering
|
41,231 | 32,513 | 77,047 | 70,684 | ||||||||||||
Total Revenues
|
$ | 104,459 | $ | 101,834 | $ | 200,772 | $ | 218,636 | ||||||||
Gross Profit:
|
||||||||||||||||
Life Sciences
|
$ | 8,115 | $ | 7,244 | $ | 15,409 | $ | 15,346 | ||||||||
Healthcare
|
5,752 | 6,616 | 10,721 | 14,923 | ||||||||||||
Physician
|
6,280 | 7,584 | 12,269 | 14,126 | ||||||||||||
IT and Engineering
|
15,149 | 11,953 | 27,720 | 25,986 | ||||||||||||
Total Gross Profit
|
$ | 35,296 | $ | 33,397 | $ | 66,119 | $ | 70,381 | ||||||||
Operating Income (Loss):
|
||||||||||||||||
Life Sciences
|
$ | 763 | $ | 1,034 | $ | 1,402 | $ | 2,781 | ||||||||
Healthcare
|
(1,711 | ) | (998 | ) | (3,836 | ) | (1,420 | ) | ||||||||
Physician
|
1,543 | 2,354 | 2,781 | 3,810 | ||||||||||||
IT and Engineering
|
2,737 | 1,022 | 3,977 | 2,096 | ||||||||||||
Total Operating Income
|
$ | 3,332 | $ | 3,412 | $ | 4,324 | $ | 7,267 |
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
||||||||||||||
2010
|
2009
|
2010
|
2009
|
||||||||||||
Revenues:
|
|||||||||||||||
Domestic
|
$ | 98,231 | $ | 96,988 | $ | 187,959 | $ | 208,145 | |||||||
Foreign
|
6,228 | 4,846 | 12,813 | 10,491 | |||||||||||
Total Revenues
|
$ | 104,459 | $ | 101,834 | $ | 200,772 | $ | 218,636 |
June 30,
2010
|
December 31,
2009
|
||||||
Total Assets:
|
|||||||
Life Sciences and Healthcare
|
$ | 82,790 | $ | 78,645 | |||
Physician
|
67,621 | 69,912 | |||||
IT and Engineering
|
200,783 | 194,905 | |||||
Total Assets
|
$ | 351,194 | $ | 343,462 |
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
|||||||||||||||
2010
|
2009
|
2010
|
2009
|
|||||||||||||
(Unaudited)
|
(Unaudited)
|
|||||||||||||||
Revenues
|
100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||
Cost of services
|
66.2 | 67.2 | 67.1 | 67.8 | ||||||||||||
Gross profit
|
33.8 | 32.8 | 32.9 | 32.2 | ||||||||||||
Selling, general and administrative expenses
|
30.6 | 29.4 | 30.8 | 28.9 | ||||||||||||
Operating income
|
3.2 | 3.4 | 2.1 | 3.3 | ||||||||||||
Interest expense
|
(1.5 | ) | (2.0 | ) | (1.5 | ) | (1.4 | ) | ||||||||
Interest income
|
0.0 | 0.0 | 0.0 | 0.0 | ||||||||||||
Income before income taxes
|
1.7 | 1.4 | 0.6 | 1.9 | ||||||||||||
Provision for income taxes
|
0.8 | 0.8 | 0.3 | 0.9 | ||||||||||||
Net income
|
0.9 | % | 0.6 | % | 0.3 | % | 1.0 | % |
Three months ended
June 30,
|
Change
|
|||||||||||||||
2010
|
2009
|
$ | % | |||||||||||||
Revenues by segment (in thousands):
|
(Unaudited)
|
(Unaudited)
|
||||||||||||||
Life Sciences
|
$ | 25,511 | $ | 22,749 | $ | 2,762 | 12.1% | |||||||||
Healthcare
|
19,300 | 23,252 | (3,952 | ) | (17.0% | ) | ||||||||||
Physician
|
18,417 | 23,320 | (4,903 | ) | (21.0% | ) | ||||||||||
IT and Engineering
|
41,231 | 32,513 | 8,718 | 26.8% | ||||||||||||
Total Revenues
|
$ | 104,459 | $ | 101,834 | $ | 2,625 | 2.6% |
Three months ended June 30,
|
|||||||||||||||
2010
|
2009
|
||||||||||||||
Gross Profit
|
Gross Margin
|
Gross Profit
|
Gross Margin
|
||||||||||||
Gross Profit by segment (in thousands):
|
(Unaudited)
|
||||||||||||||
Life Sciences
|
$ | 8,115 | 31.8% | $ | 7,244 | 31.8% | |||||||||
Healthcare
|
5,752 | 29.8% | 6,616 | 28.5% | |||||||||||
Physician
|
6,280 | 34.1% | 7,584 | 32.5% | |||||||||||
IT and Engineering
|
15,149 | 36.7% | 11,953 | 36.8% | |||||||||||
Total Gross Profit
|
$ | 35,296 | 33.8% | $ | 33,397 | 32.8% |
Six months ended
June 30,
|
Change
|
|||||||||||||||
2010
|
2009
|
$ | % | |||||||||||||
Revenues by segment (in thousands):
|
(Unaudited)
|
(Unaudited)
|
||||||||||||||
Life Sciences
|
$ | 48,561 | $ | 48,125 | $ | 436 | 0.9% | |||||||||
Healthcare
|
37,876 | 54,763 | (16,887 | ) | (30.8% | ) | ||||||||||
Physician
|
37,288 | 45,064 | (7,776 | ) | (17.3% | ) | ||||||||||
IT and Engineering
|
77,047 | 70,684 | 6,363 | 9.0% | ||||||||||||
Total Revenues
|
$ | 200,772 | $ | 218,636 | $ | (17,864 | ) | (8.2% | ) |
Six months ended June 30,
|
|||||||||||||||
2010
|
2009
|
||||||||||||||
Gross Profit
|
Gross Margin
|
Gross Profit
|
Gross Margin
|
||||||||||||
Gross Profit by segment (in thousands):
|
(Unaudited)
|
||||||||||||||
Life Sciences
|
$ | 15,409 | 31.7% | $ | 15,346 | 31.9% | |||||||||
Healthcare
|
10,721 | 28.3% | 14,923 | 27.3% | |||||||||||
Physician
|
12,269 | 32.9% | 14,126 | 31.3% | |||||||||||
IT and Engineering
|
27,720 | 36.0% | 25,986 | 36.8% | |||||||||||
Total Gross Profit
|
$ | 66,119 | 32.9% | $ | 70,381 | 32.2% |
Number
|
Footnote
|
Description
|
||
3.1
|
(1)
|
Certificate of Amendment of Restated Certificate of Incorporation of On Assignment, Inc.
|
||
3.2
|
(2)
|
Restated Certificate of Incorporation of On Assignment, Inc., as amended.
|
||
3.3
|
(3)
|
Amended and Restated Bylaws of On Assignment, Inc.
|
||
4.1
|
(4)
|
Specimen Common Stock Certificate.
|
||
4.2
|
(5)
|
Rights Agreement, dated June 4, 2003, between On Assignment, Inc. and U.S. Stock Transfer Corporation as Rights Agent, which includes the Certificate of Designation, Preferences and Rights of Series A Junior Participating Preferred Stock as Exhibit A, the Summary of Rights to Purchase Series A Junior Participating Preferred Stock as Exhibit B and the Form of Rights Certificate as Exhibit C.
|
||
10.1
|
(6)
|
2010 Employee Stock Purchase Plan, dated March 18, 2010. †
|
||
10.2
|
(6)
|
On Assignment, Inc. 2010 Incentive Award Plan, dated March 18, 2010. †
|
||
10.3*
|
Form of On Assignment, Inc. Stock Option Agreement. †
|
|||
10.4*
|
Form of On Assignment, Inc. Restricted Stock Unit Award Agreement. †
|
|||
31.1*
|
Certification of Peter T. Dameris, Chief Executive Officer and President pursuant to Rule 13a-14(a) or 15d-14(a).
|
|||
31.2*
|
Certification of James L. Brill, Senior Vice President of Finance and Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a).
|
|||
32.1*
|
Certification of Peter T. Dameris, Chief Executive Officer and President, and James L. Brill, Senior Vice President of Finance and Chief Financial Officer pursuant to 18 U.S.C. Section 1350.
|
|
*
|
Filed herewith.
|
†
|
These exhibits relate to management contracts or compensatory plans, contracts or arrangements in which directors and/or executive officers of the Registrant may participate.
|
(1)
|
Incorporated by reference from an exhibit filed with our Current Report on Form 8-K (File No. 0-20540) filed with the Securities and Exchange Commission on October 5, 2000.
|
(2)
|
Incorporated by reference from an exhibit filed with our Annual Report on Form 10-K (File No. 0-20540) filed with the Securities and Exchange Commission on March 30, 1993.
|
(3)
|
Incorporated by reference from an exhibit filed with our Current Report on Form 8-K (File No. 0-20540) filed with the Securities and Exchange Commission on May 3, 2002.
|
(4)
|
Incorporated by reference from an exhibit filed with our Registration Statement on Form S-1 (File No. 33-50646) declared effective by the Securities and Exchange Commission on September 21, 1992.
|
(5)
|
Incorporated by reference from an exhibit filed with our Current Report on Form 8-K (File No. 0-20540) filed with the Securities and Exchange Commission on June 5, 2003.
|
Incorporated by reference from our Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 27, 2010.
|
ON ASSIGNMENT, INC.
|
||
Date: August 9, 2010
|
By:
|
/s/ Peter T. Dameris
|
Peter T. Dameris
|
||
Chief Executive Officer and President (Principal Executive Officer)
|
||
Date: August 9, 2010
|
By:
|
/s/ James L. Brill
|
James L. Brill
|
||
Senior Vice President of Finance and Chief Financial Officer
|
||
(Principal Financial and Accounting Officer)
|
Date: August 9, 2010
|
|
/s/ Peter T. Dameris
|
|
Peter T. Dameris
|
|
Chief Executive Officer and President
|
Date: August 9, 2010
|
|
/s/ James L. Brill
|
|
James L. Brill
|
|
Senior Vice President of Finance and Chief Financial Officer
|
Date: August 9, 2010
|
By:
|
/s/ Peter T. Dameris
|
Peter T. Dameris
|
||
Chief Executive Officer and President
|
||
Date: August 9, 2010
|
By:
|
/s/ James L. Brill
|
James L. Brill
|
||
Senior Vice President of Finance and Chief Financial Officer
|
Participant:
|
[__________________________]
|
Grant Date:
|
[__________________________]
|
Grant Number:
|
[__________]
|
Exercise Price per Share:
|
$[_____]
|
Total Exercise Price:
|
$ [_____________]
|
Total Number of Shares Subject to the Option:
|
[_____________] shares
|
Expiration Date:
|
[__________________________]
|
Vesting Schedule:
|
[To be specified in individual agreements]
|
Dated: _______________, 2010
|
|
Signature of Spouse
|
Participant:
|
|
Grant Date:
|
|
Grant Number:
|
|
Total Number of RSUs:
|
|
Vesting Schedule:
|
Your Restricted Stock Unit grant vests and becomes exercisable over a ___ year period; ____ percent of the shares vest on the first anniversary of the grant date and the balance will vest in ___ equal _____________ installments thereafter.
|
Termination:
|
Pursuant to Section
2.5
of the Restricted Stock Unit Award Agreement, if Participant ceases to be an Employee, Consultant or Director prior to the applicable vesting date, all RSUs that have not become vested on or prior to the date of such termination of services will thereupon be automatically forfeited by Participant without payment of any consideration therefor.
|
ON ASSIGNMENT, INC.:
|
PARTICIPANT:
|
||
By:
|
|
By:
|
|
Print Name:
|
Peter Dameris
|
Print Name:
|
|
Title:
|
President and Chief Executive
Officer
|
|
|
Address:
|
26651 W. Agoura Road
|
Address:
|
|
Calabasas, CA 91302
|
Dated: _______________, 2010
|
|
Signature of Spouse
|